Abstract

Autoimmunity is a chronic process resulting in inflammation, tissue damage, and subsequent tissue remodelling and organ fibrosis. In contrast to acute inflammatory reactions, pathogenic fibrosis typically results from the chronic inflammatory reactions characterizing autoimmune diseases. Despite having obvious aetiological and clinical outcome distinctions, most chronic autoimmune fibrotic disorders have in common a persistent and sustained production of growth factors, proteolytic enzymes, angiogenic factors, and fibrogenic cytokines, which together stimulate the deposition of connective tissue elements or epithelial to mesenchymal transformation (EMT) that progressively remodels and destroys normal tissue architecture leading to organ failure. Despite its enormous impact on human health, there are currently no approved treatments that directly target the molecular mechanisms of fibrosis. The primary goal of this review is to discuss the most recent identified mechanisms of chronic autoimmune diseases characterized by a fibrotic evolution with the aim to identify possible common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.

MeSH

Autoimmune Diseases, Autoimmunity, Therapeutics, Fibrosis, Tissues

Cited by

• Epigenetic Regulation of EMP/EMT-Dependent Fibrosis. Int J Mol Sci, 2024
• Periostin and rheumatic diseases: early insights from a systematic review and meta-analysis. Clin Exp Med, 2025
• Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. J Clin Med, 2024